Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which received tocilizumab in variable standard doses (< 400 mg, 400–800 mg or > 800 mg), either at the viral (1–7 days post-symptom onset), early inflammatory (8–15) or late inflammatory (16 or more) stages, and compared it with standard treated patients. Mortality, reduced respiratory support requirements and pathology markers were measured. Tocilizumab significantly reduced the respiratory support requirements (OR 2.71, CI 1.37–4.85 at 95%) and inflammatory markers (OR 4.82, CI 1.4–15.8) of all patients, but mortality was only reduced (4.1% vs 25.7%, p = 0.03) when the drug was administered at the early inflammatory stage and in doses ranging 400–800 mg in severely-ill patients. Despite the apparent inability of Tocilizumab to prevent the progression of COVID-19 into a critical presentation, severely-ill patients may be benefited by its use in the early inflammatory stage and moderate doses.
COVID-19 pandemics has spread at a fast rate worldwide, producing multiple collapses in the healthcare system worldwide. In such setting, the correct priorization of regular hospital beds and intensive care unit beds is mandatory in order to save more lives and optimize resource usage. Currently, some specific online calculators are available, and prognostic clinical scores like NEWS and SOFA have been repurposed to evaluate potential for disease progression in COVID-19 patients. Nonetheless, the predictive value of these tools has been low in practice. Nowadays, the knowledge about pathological markers is more advanced, and unlike when the aforementioned studies were published, it is now recognized that COVID-19 has at least three different symptomatic stages, each governed by distinctive pathophysiological traits. Thus, we think that a risk calculator that incorporates the aforementioned knowledge may have a strong predictive ability.
Background: drug-drug interactions are a frequent cause of adverse drug reactions, the use of more than 5 drugs is significantly related to serious interactions. Comorbidities in patients have precipitated the frequency of polypharmacy, which produces an enhanced incidence of morbidity and mortality, hospital stay and costs. Materials and methods: 50 records of hospitalized patients were analyzed in the period from May to July 2019, a search for drug interactions was carried out with the help of Medscape Drug-Interactions Checker and the Drugs Interactions Checker. Results: 68% of the records presented at least one pharmacological interaction, the majority associated with musculoskeletal pathology and abdominal pain syndrome (45 and 29%, respectively). On the other hand, 48% of the interactions were related to the use of non-steroidal anti-inflammatory drugs and the use of opioid pain relievers combined with sedatives or anesthetics. Conclusions: there is a significant incidence in drug interactions, most of them related to poor pain management, however, it is essential to know the pathophysiology of each patient's disease, and to understand that the benefit must be greater than the risk when indicating the best therapy for the patient.
5 January 2022 in Pädi Boletín Científico de Ciencias Básicas e Ingenierías del ICBI
La COVID-19 tiene un espectro clínico variable, desde una infección asintomática hasta una enfermedad crítica con desenlace mortal. Se han propuesto múltiples terapias, algunas con efectos a nivel de la respuesta inmunológica. En este estudio evaluamos el uso de Tocilizumab, Colchicina y Baricitinib en pacientes hospitalizados con infección por SARS-CoV-2. Se examinaron los expedientes clínicos de 133 pacientes hospitalizados con COVID-19 en 3 hospitales. Inicialmente, ninguno de estos medicamentos mostró ser superior al grupo Control en disminuir la mortalidad. Sin embargo, se realizó un análisis estratificado evidenciando que Tocilizumab puede reducir la mortalidad hasta un 3.7% vs 28.12% (p=0.01). La estancia intrahospitalaria fue mayor en los pacientes que recibieron Baricitinib y Tocilizumab comparados con el Control (14.25±2.06 y 10.58±3.66 respectivamente vs 8.30±2.86). Finalmente, Tocilizumab fue el único fármaco que redujo la probabilidad de un aumento en el requerimiento de oxígeno suplementario (OR 0.3094, 0.95% IC [0.1031-0.9287]). La terapia inmunorreguladora muestra ser útil para el manejo de pacientes con COVID-19.